Literature DB >> 21655155

Uptake of novel medical therapies in the general population.

C M Booth1, B Rapoport.   

Abstract

Keywords:  Outcomes research; breast cancer; chemotherapy; health services; supportive care

Year:  2011        PMID： 21655155      PMCID： PMC3108862          DOI： 10.3747/co.v18i3.858

Source DB:  PubMed          Journal:  Curr Oncol        ISSN： 1198-0052            Impact factor:   3.677


× No keyword cloud information.
  21 in total

Review 1.  Uses of ecologic studies in the assessment of intended treatment effects.

Authors:  P A Groome; W J Mackillop
Journal:  J Clin Epidemiol       Date:  1999-09       Impact factor: 6.437

2.  Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

Authors:  Henri Roché; Pierre Fumoleau; Marc Spielmann; Jean-Luc Canon; Thierry Delozier; Daniel Serin; Michel Symann; Pierre Kerbrat; Patrick Soulié; Françoise Eichler; Patrice Viens; Alain Monnier; Anita Vindevoghel; Mario Campone; Marie-Josèphe Goudier; Jacques Bonneterre; Jean-Marc Ferrero; Anne-Laure Martin; Jean Genève; Bernard Asselain
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

3.  The value of phase 4 clinical testing.

Authors:  Gus J Vlahakes
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

4.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

5.  In defense of pharmacoepidemiology--embracing the yin and yang of drug research.

Authors:  Jerry Avorn
Journal:  N Engl J Med       Date:  2007-11-29       Impact factor: 91.245

6.  First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Authors:  Charles L Vogel; Marek Z Wojtukiewicz; Robert R Carroll; Sergei A Tjulandin; Luis Javier Barajas-Figueroa; Brian L Wiens; Theresa A Neumann; Lee S Schwartzberg
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

7.  Uses of ecologic studies in the assessment of intended treatment effects.

Authors:  S W Wen; M S Kramer
Journal:  J Clin Epidemiol       Date:  1999-01       Impact factor: 6.437

8.  Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.

Authors:  F A Holmes; S E Jones; J O'Shaughnessy; S Vukelja; T George; M Savin; D Richards; J Glaspy; L Meza; G Cohen; M Dhami; D R Budman; J Hackett; M Brassard; B B Yang; B C Liang
Journal:  Ann Oncol       Date:  2002-06       Impact factor: 32.976

9.  Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.

Authors:  Minetta C Liu; George D Demetri; Donald A Berry; Larry Norton; Gloria Broadwater; Nicholas J Robert; David Duggan; Daniel F Hayes; I Craig Henderson; Alan Lyss; Judith Hopkins; Peter A Kaufman; P Kelly Marcom; Jerry Younger; Nancy Lin; Katherine Tkaczuk; Eric P Winer; Clifford A Hudis
Journal:  Cancer Treat Rev       Date:  2008-01-30       Impact factor: 12.111

Review 10.  Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

Authors:  Jeffrey Crawford; David C Dale; Gary H Lyman
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860
View more
  6 in total

1.  Rheumatoid arthritis increases the risk of nontuberculosis mycobacterial disease and active pulmonary tuberculosis.

Authors:  Jun-Jun Yeh; Yu-Chiao Wang; Fung-Chang Sung; Chia-Hung Kao
Journal:  PLoS One       Date:  2014-10-22       Impact factor: 3.240

2.  Association between Sjogren's syndrome and respiratory failure: put airway, interstitia, and vessels close together: a national cohort study.

Authors:  Jun-Jun Yeh; Hsuan-Ju Chen; Tsai-Chung Li; Yi-Sin Wong; Hsien-Chin Tang; Ting-Chun Yeh; Chia-Hung Kao
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

3.  Nontuberculous mycobacterial infection is associated with increased respiratory failure: a nationwide cohort study.

Authors:  Jun-Jun Yeh; Yu-Chiao Wang; Cheng-Li Lin; Christine Yi-Ting Chou; Ting-Chun Yeh; Bing-Tsang Wu; Fung-Chang Sung; Chia-Hung Kao
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

4.  Effect of Systemic Lupus Erythematosus on the Risk of Incident Respiratory Failure: A National Cohort Study.

Authors:  Jun-Jun Yeh; Yu-Chiao Wang; Jiunn-Horng Chen; Wu-Huei Hsu
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

5.  Clinical burden of autosomal dominant polycystic kidney disease.

Authors:  Peir-Haur Hung; Chien-Hung Lin; Kuan-Yu Hung; Chih-Hsin Muo; Mu-Chi Chung; Chao-Hsiang Chang; Chi-Jung Chung
Journal:  Aging (Albany NY)       Date:  2020-02-24       Impact factor: 5.682

6.  Polymyositis/dermatomyositis is a potential risk factor for acute respiratory failure: a pulmonary heart disease.

Authors:  Shih-Huei Syue; Yi-Hua Chang; Pei-Ju Shih; Cheng-Li Lin; Jun-Jun Yeh; Chia-Hung Kao
Journal:  Ann Transl Med       Date:  2020-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.